Olema Pharmaceuticals

Yahoo Finance • 3 days ago

Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targete... Full story

Yahoo Finance • 3 days ago

Commit To Purchase Olema Pharmaceuticals At $16, Earn 40.4% Annualized Using Options

Investors eyeing a purchase of Olema Pharmaceuticals Inc (Symbol: OLMA) shares, but tentative about paying the going market price of $20.88/share, might benefit from considering selling puts among the alternative strategies at their dispos... Full story

Yahoo Finance • 4 days ago

Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted... Full story

Yahoo Finance • 5 days ago

Biotech Stock Gets Booted in Latest Fund Update

Key Points Sold 1,447,267 shares, a net position change of $110.43 million Post-trade stake: 0 shares, $0 value The position was previously 13.8% of the fund's AUM as of the prior quarter, marking a significant portfolio shift These 10 st... Full story

Yahoo Finance • 5 days ago

Olema Pharmaceuticals (OLMA) Rethinks Competitive Edge After Roche’s Breast Cancer Trial Success

Roche recently announced positive Phase 3 trial results for its breast cancer therapy, giredestrant, which operates through a mechanism that directly parallels Olema Pharmaceuticals’ lead candidate, palazestrant. This development has been... Full story

Yahoo Finance • 6 days ago

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted... Full story

Yahoo Finance • 6 days ago

Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 130%

Biotech stock Olema Pharmaceuticals catapulted to a four-year high Tuesday after Roche unveiled positive results in breast cancer treatment. Continue Reading View Comments... Full story

Yahoo Finance • 14 days ago

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination withatirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline E... Full story

Yahoo Finance • 20 days ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted... Full story

Yahoo Finance • 25 days ago

Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted... Full story

Yahoo Finance • last month

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patientsIn the 120 mg palazestrant cohort among pat... Full story

Yahoo Finance • 2 months ago

Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is among the best fast money stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 93.6%. Following the purchas... Full story

Yahoo Finance • 2 months ago

SA Asks: Which biotechs could be acquired by year's end?

[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked... Full story

Yahoo Finance • 3 months ago

Pfizer Inc (PFE) Announces New Trial Collaboration With Olema Pharmaceuticals

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued S&P 500 Stocks to Buy Right Now. On September 2, Pfizer Inc. (NYSE:PFE) announced a new trial collaboration with Olema Pharmaceuticals for metastatic breast cancer. The study will test... Full story

Yahoo Finance • 3 months ago

Pfizer collaboration with Olema may spark future bidding war - analyst

Alexandros Michailidis Olema Pharmaceutical's (NASDAQ:OLMA [https://seekingalpha.com/symbol/OLMA]) announcement of a new clinical trial collaboration [https://seekingalpha.com/pr/20217015-olema-oncology-announces-new-clinical-trial-agreem... Full story

Yahoo Finance • 3 months ago

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

Olema Oncology Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic... Full story

Yahoo Finance • 3 months ago

Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targete... Full story

Yahoo Finance • 3 months ago

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclibOPERA-01 enrollment ongoing with top-line data expected in the second half of 2026... Full story

Yahoo Finance • 2 years ago

15 Small-Cap Stocks with High Potential

In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stock... Full story

Yahoo Finance • 2 years ago

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Olema Oncology Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile consistent with the FD... Full story